Sanofi-aventis; Bristol-Myers Squibb

30.08.2009 – 08:05
New Large-Scale, Global Study Provides Additional Information About an Intensified Dose-Regimen of PLAVIX(R) in Acute Coronary Syndrome Patients Undergoing Angioplasty
Paris, and Princeton, New Jersey (ots/PRNewswire) - -No added benefit on the composite primary end-point with the higher dose when entire ACS study population considered- -Important new findings with higher loading dose of PLAVIX(R) for heart patients undergoing coronary angioplasty (PCI)- Today, the ...
plus
05.03.2008 – 08:08
New 300mg Loading Dose Tablet for Plavix(R) Receives Positive Opinion From the European Committee for Medicinal Products (CHMP)
Paris and Princeton, New Jersey (ots/PRNewswire) - - A New Step Forward May Help Increase Appropriate Early Use of Plavix(R) by Simplifying Administration in Acute Coronary Syndrome Patients Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the ...
plus
07.09.2006 – 08:05
European Commission Expands Indication for PLAVIX(R) (clopidogrel bisulfate) Offering New Option for Patients With Most Severe Type of Heart Attack
Paris (ots/PRNewswire) - - PLAVIX indication expanded to include patients with any acute coronary syndromes (ACS) - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the European Commission has granted a new indication for the antiplatelet ...
plus